'Zyfas Medical v. Millennium Pharmaceuticals': Decision of the Supreme Court of Singapore 27 August 2020 - Case No. [2020] SGCA 84

首页> 外文期刊>IIC:International review of intellectual property and competition law >'Zyfas Medical v. Millennium Pharmaceuticals': Decision of the Supreme Court of Singapore 27 August 2020 - Case No. [2020] SGCA 84

【24h】

'Zyfas Medical v. Millennium Pharmaceuticals': Decision of the Supreme Court of Singapore 27 August 2020 - Case No. [2020] SGCA 84

机译：'Zyfas Medical v。Millennium Pharmaceuticals'：新加坡最高法院的决定2020年8月27日 - 案例编号[2020] SGCA 84

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

1. Process patents must be declared in an application for registration of a therapeutic product pursuant to reg 23(2) of the Health Products (Therapeutic Products) Regulations 2016 (S 329/2016).

机译：1.必须在2016年卫生产品（治疗产品）条例的REG 23（2）申请中宣布流行专利申请进行治疗产品（第329/2016）。

著录项

来源
《IIC:International review of intellectual property and competition law》 |2021年第2期|223-223|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Process patents; Therapeutic product; Application for registration; Generic drug; Disclosure of existing patents in patent registration application; Application for registration with false; misleading or omitted information;

机译：过程专利;治疗产品;申请注册;仿制药;披露专利注册申请中现有专利;申请注册虚假;误导或省略信息;

'Zyfas Medical v. Millennium Pharmaceuticals': Decision of the Supreme Court of Singapore 27 August 2020 - Case No. [2020] SGCA 84

摘要

著录项

相关主题

期刊订阅